About OpenEvidence

Information overload is a prevalent challenge in many high-value domains. It is an extreme challenge in medicine.

In the year 2000, just shy of 2,300 clinical trials were conducted; by 2022, that number increased more than 10x, with 32,000 clinical trials started in 2022 alone. The amount of medical research published annually is doubling every 5 years.

Such a rate of change makes it nearly impossible for the world's physicians, medical scientists, and healthcare professionals to monitor and understand all the latest research literature and clinical evidence relevant to their work. OpenEvidence is our contribution to the global effort of taming the medical information firehose: Our approach uses artificial intelligence to aggregate, synthesize, and visualize clinical evidence in understandable, clinically-useful formats that can be used to make more evidenced-based decisions and improve patient outcomes.

A drawing of a girl in a white labcoat looking through an antique microscope

At OpenEvidence, our mission is to organize the world's medical knowledge and make it more useful, open, accessible, and understandable.

Team

Daniel Nadler

Harvard Ph.D.

Founded Kensho Technologies, the most valuable A.I. acquisition in history (beating the previous record held by DeepMind)

Zachary Ziegler

Harvard Ph.D. Candidate

Worked with Alexander Rush

Jonas Wulff

MIT Post-Doc

MPI for Intelligent Systems Ph.D.

Worked with Antonio Torralba

Micah Smith

MIT Ph.D.

Worked with Kalyan Veeramachaneni, Saman Amarasinghe, and Rob Miller

Evan Hernandez

MIT Ph.D. Candidate

Working with Jacob Andreas

Eric Lehman

MIT Ph.D. Candidate

Working with Peter Szolovits

Selected publication: “Inferring Which Medical Treatments Work from Reports of Clinical Trials”

Luke Melas-Kyriazi

Oxford Ph.D. Candidate

Rhodes Scholar

Mirac Suzgun

Stanford Ph.D. Candidate

Stanford NLP Group

Fernanda Ferreira

Harvard Medical School Ph.D.

James Esdaile

Harvard Ph.D.

Kensho Technologies Alum

Haotian Cai

Kensho Technologies Alum

Nikhil Mutalik

Kensho Technologies Alum

Medical Advisors

Dr. Ram Dandillaya, M.D., FACC

Clinical Chief, Cardiology, Cedars-Sinai Medical Center

Dr. Antonio J. Forte, M.D., Ph.D.

Faculty, Mayo Clinic

Dr. Forte leads the Tissue Regeneration and Individualized Biomedical Engineering Laboratory at Mayo Clinic

Dr. Rinn Song, M.D.

Fmr. Faculty, Harvard Medical School

Clinical Scientist, Oxford University

Former Scientist, Centers for Disease Control and Prevention (CDC)

Dr. Michael Sughrue, M.D.

M.D., Columbia University

Dr. Sughrue has performed over 3000 brain surgeries to date and has published almost 200 peer-reviewed medical publications about brain tumors

Dr. Travis Zack, M.D.

M.D., Ph.D., Harvard University

Oncology Research Fellow, University of California San Francisco

Advisors and Collaborators

Dr. Daniel Kahneman

Nobel Prize Laureate

Professor Emeritus of Psychology at Princeton University

Author of Thinking, Fast and Slow

Alexander Rush

Associate Professor of Computer Science, Cornell University

Prev. Assistant Professor of Computer Science, Harvard University

FAIR Post-Doc; Advisor: Yann LeCunn

MIT Ph.D, Computer Science


News

Tweet about our paper

Read our recent paper — a collaboration between scientists from OpenEvidence’ Xyla Research Group, MIT, Harvard Medical School, The Hospital for Sick Children, and Brigham and Women’s Hospital.


Mayo Clinic's LinkedIn post about Xyla


OpenEvidence to Become a Mayo Clinic Platform Accelerate Company

As part of Mayo Clinic Platform Accelerate, OpenEvidence will collaborate with Mayo Clinic Platform to improve how health care information is structured and discovered

NEWS PROVIDED BY

Xyla Inc.

Mar 28, 2023, 05:30 ET

CAMBRIDGE, Mass., March 28, 2023 -- OpenEvidence, an AI company pursuing foundational work in aligning Large Language Models (LLMs) to the medical domain, announced today it is to become a Mayo Clinic Platform Accelerate company. As part of Mayo Clinic Platform Accelerate, OpenEvidence will collaborate with Mayo Clinic Platform to improve how health care information is structured and discovered. OpenEvidence is led by Dr. Daniel Nadler, a Harvard PhD who previously founded and sold Kensho Technologies (which, in 2018, was acquired in the largest AI deal in history, at the time).

"Too often, AI is developed far removed from the people who will ultimately use it. Gaining hands-on experience with the pain points of the modern clinical workflow will be instrumental in allowing OpenEvidence to better fulfill its mission of aligning AI to the medical domain. The only way to revolutionize healthcare is by fostering direct collaboration between clinical professionals and technology companies" says Dr. Daniel Nadler, Founder of OpenEvidence. "The Mayo Clinic transcends the notion of a mere ‘clinic.’ It is a century-old system of values for how to best incubate and innovate clinical care. These values would be as at home in Silicon Valley today as they were in Rochester Minnesota a century ago.”

In a post on LinkedIn, Mayo Clinic Platform said “OpenEvidence is using novel technology to organize the world’s medical knowledge into understandable, clinically useful formats. As part of Mayo Clinic Platform_Accelerate, they are one step closer to improving how health care information is structured.”

About OpenEvidence

OpenEvidence is pursuing foundational work in aligning Large Language Models (LLMs) to the medical domain. By analyzing medical text and extracting biomedical entities and relations from the entire history of published medical science, OpenEvidence can facilitate better real-world, evidence-based clinical decision support and medical knowledge synthesis. In so doing, OpenEvidence is fulfilling its mission of organizing the world’s medical knowledge and making it more useful.

For more information, visit www.openevidence.com/about

Contact:

News Media:

James Esdaile
VP, Research
james@xyla.com



Values

Evidence-based

OpenEvidence’s data comes directly from scientific primary sources – high-quality, peer-reviewed studies published in leading medical journals

Independent

Unbiased analysis based on public verifiable information

Open

Free and universally accessible

Complete

All the most rigorous evidence in one place, not cherry-picked studies to support an argument or medical opinion

Up-to-date

Medicine is evolving faster-than-ever and OpenEvidence's living analysis stays up-to-date along with it

Accurate

PhD-level fact-checking and world-class medical review of every article


References